NCT05408572

Study of SON-1010 (IL12-FHAB) in Healthy Adults

Name: Clinical Trial NCT05408572
Creator: Sonnet BioTherapeutics
Keywords: Healthy Adult, SON-1010 (IL12-FHAB), Phase 1, biological, clinical trial, Australia

A Phase 1, Randomized, Adaptive-Design, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-1010 (IL12-FHAB) in Healthy Adults

Sonnet BioTherapeutics·Phase 1·ClinicalTrials.gov·biologicalRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Healthy Adult
Drug/Device/Intervention: SON-1010 (IL12-FHAB)
Study type: Interventional
Intervention type: biological

Sponsor & location

Primary sponsor: Sonnet BioTherapeutics
Location: Melbourne, Australia

Timeline & enrollment

Phase: Phase 1
Start date: Jul 27, 2022
End date: Dec 30, 2022
Enrollment: 40 participants

Primary outcome

To evaluate the safety and tolerability of SON-1010 as a single-ascending dose (SAD) in healthy adults.

Summary

SB102 is a randomized, double-blind, single center, placebo-controlled study in healthy adults starting with sentinel participants at each dose level to carefully assess the safety, tolerability, PK, and PD of SON-1010.

ICD-10 classifications

Healthy person accompanying sick personObesity, unspecifiedLifestyle-related conditionAdult-onset Still diseaseObesity

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05408572
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05408572 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sonnet BioTherapeutics and is currently Recruiting. The study focuses on Healthy Adult. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.